Caris Life Sciences (NASDAQ:CAI) Reaches New 1-Year Low – Time to Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI) hit a new 52-week low on Monday . The stock traded as low as $18.61 and last traded at $18.63, with a volume of 715179 shares changing hands. The stock had previously closed at $19.53.

Analyst Ratings Changes

Several analysts have issued reports on CAI shares. Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Robert W. Baird began coverage on shares of Caris Life Sciences in a report on Tuesday, February 17th. They set an “outperform” rating and a $26.00 price objective on the stock. Evercore set a $38.00 target price on shares of Caris Life Sciences in a research note on Monday, January 5th. Finally, Canaccord Genuity Group boosted their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $31.33.

Caris Life Sciences Trading Down 9.7%

The business’s fifty day moving average price is $25.30. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $4.98 billion and a price-to-earnings ratio of -38.35.

Insider Buying and Selling

In other news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the transaction, the insider directly owned 99,571 shares in the company, valued at $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Institutional Trading of Caris Life Sciences

A number of hedge funds have recently made changes to their positions in CAI. PointState Capital LP boosted its holdings in shares of Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock worth $181,271,000 after purchasing an additional 2,834,986 shares in the last quarter. UBS Group AG boosted its stake in Caris Life Sciences by 825.9% in the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after buying an additional 1,948,107 shares in the last quarter. Balyasny Asset Management L.P. grew its position in Caris Life Sciences by 23,902.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,660,280 shares of the company’s stock valued at $44,794,000 after acquiring an additional 1,653,363 shares during the last quarter. JPMorgan Chase & Co. grew its position in Caris Life Sciences by 185.0% during the fourth quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after acquiring an additional 1,587,176 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Caris Life Sciences by 14.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after acquiring an additional 1,180,200 shares during the last quarter.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.